Abstract 7725: Integrative molecular profiling identifies predictors of response to sacituzumab govitecan in advanced prostate cancer
Jacque A. Lyman(Masonic Cancer Center), Scott M. Dehm(University of Minnesota), Braedan M. McCluskey(University of Minnesota), Todd P. Knutson(University of Minnesota), Susan F. Slovin(Cornell University), Allison Haaning(University of Minnesota), Jamie M. Sperger(University of Wisconsin–Madison), Rendong Yang(University of Minnesota System), Christos Kyriakopolous(University of Wisconsin–Madison), YINGMING LI(Masonic Cancer Center), S Tagawa(Cornell University), Joshua M. Lang(University of Wisconsin–Madison)
Cited by 0
Related Papers
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
|JAMA Oncology|2018|661
Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors
|Proceedings of the National Academy of Sciences|2003|650